The primary objective of the study is to assess the safety and tolerability of long-term treatment with BIIB019 (Daclizumab High Yield Process; DAC HYP) monotherapy in participants with relapsing remitting multiple sclerosis (RRMS) who completed Study 205MS301 (NCT01064401).
The secondary objectives of this study in this study population are as follows:
To assess the long-term immunogenicity of BIIB019
To describe MS-related outcomes, including MS relapse, disability progression, MS lesion formation, and participant-reported impact of MS, following long-term treatment with BIIB019
To assess the safety, tolerability, and efficacy of switching to BIIB019 in participants previously on long-term treatment with interferon β-1a in Study 205MS301 (NCT01064401)
To evaluate pharmacodynamic (PD) parameters that may be associated with treatment response
Visit ClinicalTrials.gov for more information.
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.